What should you know about lurbinectedin chemotherapy?

Lurbinectedin enters the bloodstream through an infusion and interferes with the activity of cancer cells. Treatment is given in cycles, with rest between doses so your body can recover. It is used in carefully selected circumstances, often after previous treatment, and suitability depends on the cancer type, earlier medicines, blood counts, liver function and general health. It is not appropriate for every tumour. Your team may review scans, symptoms and blood tests before each dose.

Before an infusion, provide a full list of medicines, supplements and allergies. The team may check blood counts and liver tests, and may prescribe medicine to reduce nausea. During treatment, report fever, unusual tiredness, bruising, bleeding, nausea, vomiting, diarrhoea or changes in breathing. Avoid starting a new medicine without checking first, because interactions can alter side effects or treatment safety. Keep an updated record of infusion dates and symptoms so the team can adjust care when needed.

Contact your oncology service urgently for fever, chills, signs of infection, unexpected bleeding, black stools, severe weakness, yellowing of the skin, dark urine, or persistent vomiting. Seek emergency help for severe breathlessness, chest pain, fainting, or swelling of the face or throat. Do not wait for the next appointment if a symptom is sudden, worsening or stopping you from drinking and taking essential medicines.

Ask why lurbinectedin is being recommended, what response will be assessed, and how often blood and liver tests are needed. Ask what symptoms require a same-day call, how nausea or fatigue can be managed, and whether any current medicine should be paused. It is also reasonable to ask what alternatives are available if side effects or scan findings lead to a change in plan.